SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific ($CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV), with many in the community expressing concerns that the deal undervalues $CORZ, particularly given its AI infrastructure potential. Some investors believe that rejecting the deal could lead to a higher valuation for $CORZ as a standalone entity or attract a better offer, while others worry about the company's future prospects without the merger.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending due to a significant drop following a lowered sales outlook, sparking discussions about consumer spending and the company's value proposition. Community members are debating whether the dip is a buying opportunity or a sign of deeper issues with the brand, citing concerns about pricing, portion sizes, and competition in the fast-casual dining sector.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending due to raised FY25 EBITDA guidance, sparking optimism about the company's future profitability. The community is discussing the potential for a significant stock re-rating and a short squeeze, with some highlighting the low P/E ratio relative to the broader market. Discussions also involve potential catalysts like government appropriations and debt refinancing.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to upcoming Phase 3 data for its DMD treatment, with investors closely watching for positive results that could lead to FDA approval; community chatter reflects both excitement and apprehension, as the data represents a pivotal moment for the company. Community members also highlight BlackRock's substantial stake in Capricor. Some traders cite the potential for a significant short squeeze based on the stock's high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December.&nbsp;The Cardiff, UK-based company's stock surge followed the U.S. FDA granting its treatment eRapa a Fast Track designation.&nbsp;The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.&nbsp;FAP currently has no effective medical treatment, with the only option being surgical resection of the colon or rectum.The Fast Track designation aims to expedite the development and review of drugs targeting serious conditions with significant unmet medical needs.&nbsp;Biodexa's Phase 2 study of eRapa showed promising results, with a median 17% reduction in total polyp burden and a 75% non-progression rate at 12 months.&nbsp;In cohort 2, patients showed an even better response, with a 29% median reduction in polyp burden and an 89% non-progression rate.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BDRX_sentiment_and_message_volume_Feb_10_2beb98885a.png" alt="BDRX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>BDRX sentiment and message volume Feb 10 as of 1:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned 'extremely bullish,' with the stock soaring to the top 10 trending symbols. The volume of messages spiked to its highest level in a year, reflecting increased excitement among investors.&nbsp;Users were optimistic about the stock's potential, with one commenting that it could hit $10 and another suggesting that it was a "last chance to buy in before it goes above $8."&nbsp;<stembedurl>https://stocktwits.com/BULLNATION1/message/603560053</stembedurl><stembedurl>https://stocktwits.com/Mr_Xray/message/603579405</stembedurl>Biodexa's stock has gained around 57% so far this year, though it is still down more than 80% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks

The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer. 

Equity

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (Biodexa or the Company) (NASDAQ: BDRX). Investors...

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm BDRX INVESTOR ALERT: Bronstein...

Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?

Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer...

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$6.05
Prev Close	$5.94
Open	$5.96
Dividend Yield	0.00%
50-Day Moving Average	$6.73
Beta	1.09
Avg. Volume	48,694.19
PE Ratio	-0.09

52-Week High	$92.00
52-Week Low	$5.00
Market Capitalization	$3.68M
EPS (Annual)	-$148.23
Price to Book	13.96
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BDRX
Biodexa Pharmaceuticals Plc

Feed

News

Sentiment

Fundamentals

Info

Latest BDRX News

BDRXBiodexa Pharmaceuticals Plc